Video

Updates on I/O Therapy for Non-Driver mNSCLC

A review of new FDA approvals in I/O therapy regarding a nivolumab/ipilimumab-based regimen as seen in the CheckMate 227 and CheckMate 9LA studies, along with considerations for immune-related adverse events.

Data from the following clinical trials are discussed:

  • CheckMate 227: Nivolumab plus ipilimumab in advanced non–small cell lung cancer (Hellmann MD et al. N Engl J Med. 2019;381:2020-2031.)

  • Nivolumab + ipilimumab versus platinum-doublet chemotherapy as first-line treatment for advanced non–small cell lung cancer: Three-year update from CheckMate 227 Part 1. (Ramalingam SS et al. 2020 ASCO annual meeting. Abstract 9500.)

  • Nivolumab + ipilimumab + 2 cycles of platinum-doublet chemotherapy vs 4 cycles chemo as first-line treatment for stage IV/recurrent non–small cell lung cancer: CheckMate 9LA. (Reck M et al. 2020 ASCO annual meeting. Abstract 9501.)

  • IMpower110: Clinical safety in a phase III study of atezolizumab monotherapy vs platinum-based chemotherapy in first-line non–small cell lung cancer. (Jassem J et al. 2020 ASCO annual meeting. Abstract e21623.)

Related Videos
Dr Cascone on Evaluating Neoadjuvant Durvalumab-Based Regimens in Resectable NSCLC
FRCSI, FRCSEd, medical director, Thoracic Cancer Program, and associate executive director, AdventHealth Cancer Institute
Benjamin P. Levy, MD, clinical director, Medical Oncology, Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital; and associate professor, oncology, Johns Hopkins University School of Medicine
Russell Hales, MD, director, Thoracic Oncology Multidisciplinary Program, associate professor, clinical radiation oncology and molecular radiation sciences, and director, thoracic multidisciplinary clinic, John Hopkins University School of Medicine
Estelamari Rodriguez, MD, MPH, associate director, Community Outreach – Thoracic Oncology, Sylvester Comprehensive Cancer Center
Misty D. Shields, MD, PhD, assistant professor, clinical medicine, Department of Medicine, Division of Hematology/Oncology, Indiana University (IU) School of Medicine; and associate member, Experimental and Developmental Therapeutics, IU Melvin and Bren Simon Comprehensive Cancer Center
Corey J. Langer, MD, director, Thoracic Oncology, Penn Medicine; and professor, medicine (hematology-oncology), the Hospital of the University of Pennsylvania, Perelman School of Medicine
Alexander I. Spira MD, PhD, FACP, FASCO
Hidehito Horinouchi, MD, PhD